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Background: Angiogenesis is essential for tumor growth. Hepatocellular carcinoma (HCC) is characterized by
hypervascularity; high levels of angiogenesis are associated with poor prognosis and a highly invasive phenotype
in HCC. Up-regulated gene-4 (URG4), also known as upregulator of cell proliferation (URGCP), is overexpressed in
multiple tumor types and has been suggested to act as an oncogene. This study aimed to elucidate the effect of
URG4/URGCP on the angiogenic capacity of HCC cells in vitro.
Methods: Expression of URG4/URGCP in HCC cell lines and normal liver epithelial cell lines was examined by Western
blotting and quantitative real-time PCR. URG4/URGCP was stably overexpressed or transiently knocked down using a
shRNA in two HCC cell lines. The human umbilical vein endothelial cell (HUVEC) tubule formation and Transwell migration
assays and chicken chorioallantoic membrane (CAM) assay were used to examine the angiogenic capacity of conditioned
media from URG4/URGCP-overexpressing and knockdown cells. A luciferase reporter assay was used to examine the
transcriptional activity of nuclear factor kappa – light – chain - enhancer of activated B cells (NF-κB). NF-κB was inhibited
by overexpressing degradation-resistant mutant inhibitor of κB (IκB)-α. Expression of vascular endothelial growth factor C
(VEGFC), tumor necrosis factor-α (TNFα), interleukin (IL)-6, IL-8 and v-myc avian myelocytomatosis viral oncogene homolog
(MYC) were examined by quantitative real-time PCR; VEGFC protein expression was analyzed using an ELISA.
Results: URG4/URGCP protein and mRNA expression were significantly upregulated in HCC cell lines. Overexpressing
URG4/URGCP enhanced - while silencing URG4/URGCP decreased - the capacity of HCC cell conditioned media to
induce HUVEC tubule formation and migration and neovascularization in the CAM assay. Furthermore, overexpressing
URG4/URGCP increased - whereas knockdown of URG4/URGCP decreased - VEGFC expression, NF-κB transcriptional
activity, the levels of phosphorylated (but not total) IκB kinase (IKK) and IκB-α, and expression of TNFα, IL-6, IL-8 and MYC in
HCC cells. Additionally, inhibition of NF-κB activity in HCC cells abrogated URG4/URGCP-induced NF-κB activation and
angiogenic capacity.
Conclusions: This study suggests that URG4/URGCP plays an important pro-angiogenic role in HCC via a mechanism
linked to activation of the NF-κB pathway; URG4/URGCP may represent a potential target for anti-angiogenic
therapy in HCC.
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Angiogenesis, the formation of new blood vessels, occurs
during numerous physiological and pathological pro-
cesses [1]. Angiogenesis is required to maintain tumor
growth and metastasis, and constitutes an important
hallmark of tumor progression [2-5]. Tumor angiogen-
esis is the generation of a network of blood vessels that
penetrates into the tumor to supply the nutrients and
oxygen required to maintain and enable tumor growth
and invasion. Consequently, blocking tumor angiogen-
esis could prevent the formation of tumor blood vessels
and inhibit or slow the growth and spread of tumor cells
[6-8]. Angiogenesis is widely regarded to be an effective
therapeutic target and promising biomarker for the diag-
nosis of cancer; therefore, angiogenesis is an important
field of research in biological and clinical oncology
[9-13]. Tumor angiogenesis is a consequence of an im-
balance between pro-angiogenic factors, such as the vas-
cular endothelial growth factor (VEGF) family and IL-8/
CXCL8, and inhibitors of angiogenesis, including endo-
statin, angiostatin and other related molecules [14-16].
VEGF regulates the sprouting and proliferation of endo-
thelial cells and can stimulate tumor angiogenesis [17].
A number of currently-used anti-angiogenesis drugs
function by inhibiting pro-angiogenic factors, for ex-
ample the monoclonal antibody bevacizumab binds to
VEGF and prevents it from binding to the VEGF receptors,
and sunitinib and sorafenib are small molecules that attach
to VEGF-R and inhibit the binding of VEGF [18,19]. How-
ever, the precise regulation and mechanisms of tumor
angiogenesis are not yet fully explored and the identifica-
tion of other novel specific, effective inhibitors of angio-
genesis is urgently required to treat patients with cancer.
Hepatocellular carcinoma (HCC) accounts for 90% of
all primary malignant liver cancers and is the fifth most
common cancer and third most common cause of
cancer-related mortality worldwide [20,21]. HCC has a
much higher morbidity in Asia due to the high incidence
of hepatitis B virus (HBV) and hepatitis C virus (HCV)
infection, especially in China where 55% of all cases of
HCC worldwide occur [21]. HCC is characterized by
hypervascularity indicative of angiogenesis, and tumor
growth in HCC relies on the formation of new blood
vessels [15]. VEGF has been reported to a play critical
role in angiogenesis in HCC [22]. Targeting angiogenesis
using pharmacologic strategies has recently been vali-
dated in several other solid tumor types [23]. Therefore,
identification of an anti-angiogenic strategy for HCC
may help to improve the treatment outcomes and ex-
tend survival for patients with HCC.
Up-regulated gene-4 (URG4), also known as upregula-
tor of cell proliferation (URGCP), is located on chromo-
some 7p13 and was identified and initially characterized
by Tufan et al. URG4/URGCP is upregulated in thepresence of hepatitis B virus X antigen (HBxAg) and
contributes to the development of HCC as it can pro-
mote hepatocellular growth and survival both in vitro
and in vivo [24]. Previous studies demonstrated that
URG4/URGCP is upregulated in human HCC and gastric
cancer and URG4/URGCP could promote the prolifera-
tion and tumorigenicity of HCC and gastric cancer cells
[25,26]. Based on these findings, URG4/URGCP has been
suggested to function as an oncogene in multiple tumor
types [25-28]. However, the effect of URG4/URGCP on
tumor angiogenesis in HCC has not yet been elucidated.
In the present study, we demonstrate that URG4/
URGCP is upregulated in HCC cell lines. Additionally,
ectopic overexpression of URG4/URGCP enhanced the
angiogenic capacity of HCC cells in vitro and also upreg-
ulated VEGF and activated the NF-κB signaling pathway,
whereas knockdown of URG4/URGCP had the opposite
effects. This study demonstrates that URG4/URGCP
may promote angiogenesis and the expression of VEGF-
C in HCC by activating the NF-κB signaling pathway;
therefore, URG4/URGCP may have potential as a thera-
peutic target in HCC.
Methods
Cells and treatments
The normal liver epithelial cell lines Lo2 and THLE3
were purchased from and cultured as recommended by
the American Type Culture Collection (Manassas, VA,
USA). The HCC cell lines Hep3B, MHCC97H, HepG2,
SMMC-7721, QGY-7703, Huh7 and BEL-7402 were pur-
chased from the ATCC and cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum
(FBS) and 100 U penicillin-streptomycin (Invitrogen) in
a humidified incubator at 37°C in 5% CO2.
Vectors, retrovirus infection and transfection
The URG4/URGCP expression construct was generated by
sub-cloning PCR-amplified full-length human URG4/
URGCP cDNA into pMSCV-retro-puro (Promega, Madison,
WI, USA) using the forward primer 5′-CCAGATCTAC
CATGG CGTCGCCCGGGCATTC-3′ and reverse primer
5′-GCCGAATTCTCACAGC CGTCTCACCAGCT-3′.
To knockdown URG4/URGCP, a siRNA sequence tar-
geting human URG4/URGCP (5′-ACCAAAGACTTG
CCCTGGAATT-3′; synthesized by Invitrogen) was cloned
into pSuper-retro-puro (Promega) to generate pSuper-
retro-URG4/URGCP-RNAi (referred to as URG4-Ri) [26].
Retrovirus generation and infection were performed as de-
scribed previously [29].
The vector pBabe-Puro-IκBα-mut, which expresses
degradation-resistant IκBα mutant protein (referred to
as IκBα-mut), was purchased from Addgene (plasmid
15291; Cambridge, MA, USA) and used as a NF-κB
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pBabe-Puro-IκBα-mut using Lipofectamine 2000 reagent
(Invitrogen) according the manufacturer’s instructions.
Quantitative real-time RT-PCR
Total cellular RNA was extracted using TRIzol reagent
(Invitrogen) and 2 μg of RNA was subjected to cDNA
synthesis using random hexamers. Quantitative real-
time RT-PCR (qRT-PCR) was performed using an Ap-
plied Biosystems 7500 Sequence Detection system with
an initial denaturation step at 95°C for 10 min,
followed by 28 cycles of denaturation at 95°C for
60 sec, primer annealing at 58°C for 30 sec and primer
extension at 72°C for 30 sec, with a final extension step
at 72°C for 5 min. Target gene expression was calcu-
lated using the threshold cycle (Ct) values and the for-
mula 2-[(Ct of Genes) – (Ct of GAPDH)] relative to the
internal control gene GAPDH. PCR primers were de-
signed using Primer Express version 2.0 (Applied Biosys-
tems, Foster City, CA, USA) and were as follows: VEGFC




forward: 5′-TCTCCACAAGCGCCTTCG-3′ and 5′-CTC
AGGGCTGAGATGCCG; IL-8 forward: 5′-TGCCAAG
GAGTGCTAAAG-3′ and reverse: 5′-CTCCACAACCC
TCTGCAC-3′; MYC forward: 5′-TCAAGAGGCGAA
CACACAAC-3′ and reverse: 5′-GGCCTTTTCATTGT
TTTCCA-3′; GAPDH forward: 5′-ATTCCACCCATGG
CAAATTC-3′ and reverse: 5′-AGAGGCAGGGATGA
TGTTCTG-3′.
Western blotting
Total cellular protein was extracted and the samples
were heated at 100°C for 5 min. Samples containing
20 μg protein were separated by SDS-PAGE, electro-
blotted onto PVDF membranes (Millipore, Billerica,
MA, USA), blocked in non-fat milk, probed with poly-
clonal rabbit anti-URG4 (Abcam, Cambridge, MA,
USA), anti-IKK, anti-phosphorylated-IKK (p-IKK), anti-
IκBα or anti-p-IκBα (p-IκBα; all Cell Signaling, Danvers,
MA, USA). The membranes were stripped and re-
probed using anti-α-Tubulin (Cell Signaling) as a loading
control.
HUVEC tubule formation assay
The HUVEC tubule formation assay was performed as
previously reported [23]. Briefly, 200 μl Matrigel was
placed into each well of a 24-well plate and polymerized
for 30 min at 37°C. HUVECs (approximately 2 × 104) in
200 μl conditioned media (CM) from indicated HCC
cells were added to each well and incubated for 24 h at
37°C in 5% CO2. Images were captured at 100× using abright-field microscope, and formation of capillary tubes
was quantified by measuring their total length of each
image.
Chicken chorioallantoic membrane assay
The chicken chorioallantoic membrane (CAM) assay
was performed using eight-day-old fertilized chicken
eggs. A 1 cm diameter window was created in the shell
of each egg and the surface of the dermic sheet was
removed to expose the CAM. A 0.5 cm diameter filter
paper was placed on top of the CAM, and 100 μl CM
harvested from the indicated HCC cells placed on the
center of the filter paper. The eggs were incubated at 37°C
at 80-90% relative humidity for 48 h, then the windows in
the shell were closed using sterilize bandages. Following
fixation with stationary solution (1:1 vol/vol mixture of
methanol and acetone) for 15 min, the CAM was excised
and imaged using a digital camera. The number of
second- and third-order vessels in the test groups was
expressed relative to that of CAM treated with CM from
the vector control cells.
HUVEC transwell migration assay
HUVECs (approximately 1 × 104) were plated on the top
of polycarbonate Transwell filters (pore size 8.0 μm;
Corning Incorporated, Corning, NY, USA ) in CM con-
taining 5% FBS. The lower chamber was filled with
500 μl of media containing 15% FBS. The cells were in-
cubated at 37°C for about 20 h, and the cells that mi-
grated to the lower membrane surface were fixed in 4%
paraformaldehyde, stained using hematoxylin for
15 min, and the number of cells in ten randomly-
selected 200× fields of view per filter was counted and
expressed relative to that of cells treated with CM from
vector control cells.
Luciferase reporter assay of NF-κB transcriptional activity
The pNF-κB-luciferase reporter and control plasmids
(Clontech, Mountain View, CA, USA) were used exam-
ine NF-κB transcriptional activity. Approximately 1.5 ×
104 HCC cells were seeded in triplicate in 24-well plates,
allowed to adhere, and co-transfected with 100 ng of the
NF-κB luciferase reporter plasmid or control luciferase
plasmid and 1 ng of pRL-TK Renilla plasmid (Promega)
using Lipofectamine 2000 reagent (Invitrogen). The lu-
ciferase and Renilla signals were measured 48 h after
transfection using the Dual Luciferase Reporter Assay
Kit (Promega) according to the manufacturer’s protocol.
Enzyme-linked immunosorbent assay
The VEGFC enzyme-linked immunosorbent assay (ELISA)
was performed using a commercial kit according to the
manufacturer’s instructions (Keygentec Co., Shanghai,
China). Briefly, standard solutions, test samples and
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triplicate, incubated at 36°C for 90 min, washed, incu-
bated with a specific anti-VEGFC antibody (Cell Signal-
ing) at 36°C for 1 h, washed, incubated with secondary
antibody from the kit for 1 h, substrate was added, in-
cubated for 1 h and the absorbance values were read at
OD450 using an ELISA plate reader.
Statistical analysis
All experimental data are presented as the mean ± SD of
three independent biological replicates. Statistical ana-
lyses were performed using SPSS 13.0 (IBM, Armonk, NY,
USA). Analysis of variance (ANOVA) was used to evaluate
the significance of the differences between two groups.
P-values ≤ 0.05 were considered statistically significant.
Results
URG4/URGCP is upregulated in HCC cell lines
Western blotting and qRT-PCR analyses were performed
to examine URG4/URGCP protein and mRNA expressionFigure 1 URG4/URGCP is upregulated in HCC cell lines. A. Western blotting
lines and seven HCC cell lines; α-Tubulin was used as a loading control. Lo
B. Real-time PCR quantification of URG4/URGCP mRNA expression in two no
normalized to GAPDH and expressed relative to Lo2 cells. Data is mean ± Sin HCC cell lines. URGCP/URG4 protein expression was
significantly upregulated in all seven HCC cell lines tested
compared to two normal liver epithelial cell lines, Lo2 and
THLE3, which expressed low or undetectable levels of
URGCP/URG4 (Figure 1A). Consistent with the Western
blotting analysis, qRT-PCR demonstrated that URG4/
URGCP mRNA was markedly upregulated in all seven
HCC cell lines compared to the normal liver epithelial cell
lines (Figure 1B). These data suggest that URG4/URGCP
is upregulated in HCC cells.
URG4/URGCP promotes the angiogenic capacity and
expression of VEGFC in HCC cells
The HCC cell lines QGY7703 and Hep3B expressed
moderate levels of URG4/URGCP and were used to cre-
ate stable cell lines overexpressing URG4/URGCP. Over-
expression of URG4/URGCP in the stable cell lines was
verified by Western blotting (Figure 2A).
Firstly, the effect of URG4/URGCP on the ability of
HCC cells to induce angiogenesis was investigated usinganalysis of URG4/URGCP protein expression in two normal liver cell
wer panel, quantification of Western blotting data relative to Lo2 cells.
rmal liver cell lines and seven HCC cell lines. Transcript levels were
D of three independent experiments; ** P < 0.01.
Figure 2 URG4/URGCP enhances the angiogenic capacity of HCC cells in vitro. A. Western blotting analysis of URG4/URGCP protein expression in
QGY7703 - vector, QGY7703-URG4/URGCP, Hep3B-vector and Hep3B-URG4/URGCP cells; α-Tubulin was used as a loading control. The numbers
represent the relative expression of each protein compared to the respective control cells. B. Representative images (left) and quantification (right)
of tube-like structures formed by HUVECs on Matrigel-coated plates when cultured in conditioned medium (CM) derived from the indicated cells.
C. Representative images (left) and quantification (right) of the number of migrated HUVEC cells after incubation in CM derived from the indicated
cells in the Transwell migration assay. D. Representative images (left) and quantification (right) of neovessels formed in the CAM assay when
stimulated by CM derived from the indicated cells. E. Quantitative real-time PCR analysis of VEGFC mRNA expression in the indicated cells.
Transcript levels were normalized to GAPDH and expressed relative to the respective control cells. F. ELISA of VEGFC protein expression in the
indicated cell supernatants. Data is mean ± SD of three independent experiments; * P < 0.05.
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seeded on Matrigel in CM harvested from URG4/
URGCP-overexpressing HCC cells. CM derived from
URG4/URGCP-transduced cells significantly increased
the formation of tubule structures compared to CM
from vector control cells (Figure 2B). Moreover, CM from
URG4/URGCP-overexpressing HCC cells significantlyincreased the migration of HUVEC cells in the migration
assay (Figure 2C). Furthermore, ectopic overexpression of
URG4/URGCP in HCC cells enhanced the ability of CM
to induce the formation of second- and third-order vessels
in the CAM assay (Figure 2D).
As neovessel formation is closely associated with
VEGFC, we examined the expression of VEGFC in
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cells using qRT-PCR and an ELISA. VEGFC mRNA and
protein expression were significantly upregulated in the
URG4/URGCP-overexpressing HCC cells (Figure 2, E
and F). However, the results were not repeated when
these experiments were performed with Lo2 and THLE3
cells stably overexpressing URG4/URGCP (Additional
file 1: Figure S1). Taken together, these results suggest
that URG4/URGCP enhanced the capacity of HCC cells
to induce neovessel formation in vitro.Silencing URG4/URGCP reduces the angiogenic capacity
and expression of VEGFC in HCC cells
To further confirm the effect of URG4/URGCP on
angiogenesis during the progression of HCC, stable
QGY7703 and Hep3B cell lines in which URG4/URGCP
was silenced were established; knockdown of URG4/
URGCP in these cells was confirmed by Western blot-
ting (Figure 3A). Compared to CM from vector control
cells, CM from URG4/URGCP-silenced cells inhibited
tubule formation by HUVECs (Figure 3B), suggesting
that knockdown of endogenous URG4/URGCP reduced
the ability of HCC cells to promote angiogenesis. More-
over, CM from URG4/URGCP-silenced HCC cells inhib-
ited HUVEC migration (Figure 3C) and decreased the
formation of second- and third-order vessels in the CAM
assay (Figure 3D). In parallel with these results, knock-
down of URG4/URGCP significantly reduced VEGFC
mRNA and protein expression in both HCC cell lines
(Figure 3E and F). These results confirmed that URG4/
URGCP enhances the angiogenic capacity of HCC cells.URG4/URGCP promotes the angiogenic capacity of HCC
cells via activating the NF-κB signaling pathway
As VEGFC has been reported to be a downstream target
of the NF-κB pathway [30-33], we explored effect of
URG4/URGCP on NF-κB signaling activity. Luciferase
reporter assays demonstrated that overexpression of
URG4/URGCP enhanced the transcriptional activity of a
NF-κB reporter gene, while knockdown of URG4/URGCP
suppressed NF-κB transcriptional activity (Figure 4A).
Western blotting showed that overexpression of URG4/
URGCP increased the levels of phosphorylated IKK and
phosphorylated IκBα but did not significantly change
the total protein level of IKK or IκBα (Figure 4B). In
addition, the levels of number of NF-κB target genes,
including TNF-α, IL-6, IL-8 and MYC, were upregulated
in URG4/URGCP-overexpressing cells and downregu-
lated in URG4/URGCP-silenced HCC cells (Figure 4C).
Taken together, these results indicated that the NF-κB
pathway may underlie the pro-angiogenic effect of
URG4/URGCP in HCC.Inhibition of NF-κB signaling activity inhibits the ability of
URG4/URGCP to enhance the angiogenic capacity of HCC
cells
We further explored whether URG4/URGCP increased
the angiogenic capacity of HCC cells by activating NF-
κB signaling. NF-κB signaling was inhibited by transient
overexpression of a non-degradable IκBα mutant con-
taining alanine residues in positions 32 and 36 instead of
serine residues, which cannot be phosphorylated and de-
graded [34] and thus remains bound to and inhibits NF-
κB. The stimulatory effects of CM derived from URG4/
URGCP-overexpressing HCC cells on HUVEC tubule
formation and migration were significantly reversed
when the IκBα mutant was transiently overexpressed in
the HCC cells (Figure 5, A-C; Additional file 2: Figure S2).
Similar results were obtained in the CAM assay, as the
IκBα mutant reversed the ability of CM collected from
URG4/URGCP-overexpressing HCC cells to promote
angiogenesis (Figure 5D). Collectively, these data suggest
that URG4/URGCP enhances the angiogenic capacity of
HCC cells via a mechanism involving functional activation
of the NF-κB signaling pathway.
Discussion
URG4/URGCP can promote the growth and survival of
HCC cells and was the first gene identified to be upregu-
lated in the presence of HBxAg [24], indicating URG4/
URGCP may potentially play a role in the progression of
HCC. Besides its ability to promote HCC cell prolifera-
tion, the precise role of URG4/URGCP in HCC has not
yet been elucidated [24,26]. In this study, we demon-
strate for the first time that URG4/URGCP can enhance
the angiogenic capacity of HCC cells in vitro; therefore,
URG4/URGCP may exert a number of functions during
the development and progression of HCC and should be
considered as a potential novel therapeutic target for
HCC. Besides the hepatocarcinogenesis function of
URG4/URGCP, it has been reported that URG4/URGCP
is also upregulated in gastric cancer tissues and cells and
enhances gastric cancer cell proliferation and tumorigen-
esis [25]. High expression level of URG4 was also found
in acute lymphoblastic leukemia (ALL) patients indicat-
ing that URG4 might be involved in leukemogenesis
[35]. However, future studies are needed to demonstrate
the exact role of URG4 in various malagnancies.
Although several studies have indicated that URG4/
URGCP may act as an oncogene in various tumor types
[26,36-38], the exact function and molecular mechanism
of actions of URG4/URGCP have not been precisely
characterized. In the present study, we found that over-
expression of URG4/URGCP increased the formation of
tubule structures in HUVEC cells and significantly in-
creased the migration of HUVEC cells in the migration
assay, and enhanced the ability to induce the formation
Figure 3 Knockdown of URG4/URGCP reduces the angiogenic capacity of HCC cells in vitro. A. Western blotting analysis of URG4/URGCP protein
expression in URG4/URGCP-shRNA-transduced QGY7703 and Hep3B cell lines (shown as URG4/URGCP-RNAi) and the corresponding vector control
cells; α-Tubulin was used as a loading control. The numbers represent the relative expression of each protein compared to the respective control
cells. B. Representative images (left) and quantification (right) of tube-like structures formed by HUVECs on Matrigel-coated plates when cultured
in conditioned medium (CM) derived from the indicated cells. C. Representative images (left) and quantification (right) of the number of migrated
HUVEC cells when incubated in CM derived from the indicated cells in the Transwell migration assay. D. Representative images (left) and quantification
(right) of neovessels formed in the CAM assay when stimulated by CM derived from the indicated cells. E. Quantitative real-time PCR analysis of VEGFC
mRNA expression in the indicated cells. Transcript levels were normalized to GAPDH and expressed relative to the respective control cells. F. ELISA of
VEGFC protein expression in the indicated cell supernatants. Data is mean ± SD of three independent experiments; * P < 0.05.
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results indicate the promotive effect of URG4/URGCP
in HCC angiogenic progression. In combination with the
ability of URG4/URGCP to promote the angiogenic cap-
acity of HCC cells, VEGFC was markedly upregulated in
URG4/URGCP-overexpressing cells, indicating that anassociation exists between URG4/URGCP and VEGFC.
VEGFC is one of the target genes downstream of the
NF-κB pathway [30-33]. Luciferase reporter assays
showed overexpression of URG4/URGCP significantly
enhanced the transcriptional activity of NF-κB, suggest-
ing NF-κB plays an essential role in the URG4/URGCP-
Figure 4 URG4/URGCP promotes NF-κB transcriptional activity. A. Luciferase reporter assay of NF-κB transcriptional activity in URG4/URGCP-over-
expressing or silenced cells expressed relative to the respective control cells. B. Western blotting analysis of the expression of phosphorylated IKK
(p-IKK), total IKK, phosphorylated IκBα (p-IκBα) and total IκBα; α-Tubulin was used as a loading control. The numbers represent the relative expression
of each protein compared to the respective control cells. C. Quantitative real-time PCR analysis of the expression of genes downstream of NF-κB in the
indicated cells; transcript levels were normalized to GAPDH and expressed relative to the respective vector control cells. Data is mean ± SD of three
independent experiments; * P < 0.05.
Xing et al. BMC Cancer  (2015) 15:368 Page 8 of 12induced angiogenic capacity of HCC cells. NF-κB has
been widely studied as a transcription factor that regu-
lates inflammatory and immune responses, as well asrange of other physiological and pathological processes
including the development and progression of cancer
[39,40]. Aberrant activation of NF-κB is observed in a
Figure 5 (See legend on next page.)
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Figure 5 URG4/URGCP enhances the angiogenic capacity of HCC cells via activating the NF-κB pathway. URG4/URGCP-overexpressing HCC cells
were transfected with a non-degradable mutant IκBα protein, which acts as a specific NF-κB inhibitor. A. Luciferase reporter assay of NF-κB
transcriptional activity in the indicated cells. B. Representative images (left) and quantification (right) of tube-like structures formed by HUVECs on
Matrigel-coated plates in the presence of CM from the indicated cells. C. Representative images (left) and quantification (right) of the number of
migrated HUVEC cells in the Transwell migration assay after incubation in CM derived from the indicated cells. D. Representative images (left) and
quantification (right) of neovessels formed in the CAM assay when stimulated by CM derived from the indicated cells. Data is mean ± SD of three
independent experiments; *P < 0.05.
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biological processes in cancer cells by transcriptionally
activating numerous target genes [41,42]. Activation of
NF-κB signaling is negatively regulated by the IκBs,
which bind and sequester NF-κB in the cytoplasm in an
inactive state. IκBs are phosphorylated by IKKs, which
leads to ubiquitin-mediated degradation of the IκBs and
consequently enables the release and translocation of
NF-κB to the nucleus [43-45]. Consistent with these
well-studied processes, the present study demonstrated
that overexpression of URG4/URGCP upregulated the
level of p-IKK and p-IκBα and ultimately enhanced the
activation of NF-κB. Additionally, when the cells overex-
pressing URG4/URGCP were transfected with the IκBα
mutant, the capacity of CM from URG4/URGCP-over-
expressing cells to enhance the angiogenic capacity of
HCC cells was attenuated. These findings indicate that
URG4/URGCP promotes the angiogenic capacity of
HCC cells - at least in part - by activating the NF-κB/
VEGFC signaling pathway.
Additionally, overexpression of URG4/URGCP upreg-
ulated a number of genes downstream of the NF-κB sig-
naling pathway: TNF, IL-6, IL-8 and MYC. TNF-α is
well-recognized to promote angiogenesis and drive re-
modeling of blood vessels in vivo [46-48]; interleukin-6
increases the expression of VEGF and can promote
angiogenesis [49-51]; IL-8 has been shown to play an
important role in tumor angiogenesis [52]; and Myc
plays an essential role in vasculogenesis and angiogenesis
during the development and progression of various types
of cancer [53-55]. It would be interesting to explore
whether TNF, IL-6, IL-8 or MYC play a role in angiogen-
esis and disease progression in HCC, and explore the
correlation between the expression of these genes and
VEGFC. The regulatory mechanism by which upregula-
tion of URG4/URGCP modulates the NF-κB/VEGFC
pathway and enhances the angiogenic capacity of HCC
cells remains to be elucidated and should be investigated
further.
Conclusion
In conclusion, this study demonstrates that URG4/
URGCP is upregulated in HCC cell lines and enhances
the angiogenic capacity of HCC cells via activation of
the NF-κB signaling pathway. These results may providenew insight into the mechanisms that regulate angiogen-
esis in HCC; targeting URG4/URGCP may represent a
promising therapeutic strategy for HCC.Additional files
Additional file 1: Figure S1. Effect of URG4/URGCP on the angiogenic
capacity of normal hepatic cell lines. A. Western blotting analysis of
URG4/URGCP protein expression in Lo2 and THLE3 cells transduced with
either pMSCV-URG4/URGCP or the control vector pMSCV; α-Tubulin was
used as a loading control. B. Representative images (left) and quantification
(right) of tube-like structures formed by HUVECs cultured on Matrigel-coated
plates in the presence of CM from the indicated cells. C. Representative
images (left) and quantification (right) of the number of migrated HUVEC
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the indicated cells. D. Representative images (left) and quantification (right)
of neovessels formed in the CAM assay when stimulated by CM derived
from the indicated cells. E. Quantitative real-time PCR analysis of VEGFC
mRNA expression in the indicated cells; transcript levels were normalized to
GAPDH and expressed relative to the respective vector control cells. F. ELISA
of VEGFC protein expression in the indicated cell supernatants. Data is
mean ± SD of three independent experiments; * P < 0.05.
Additional file 2: Figure S2. Western blotting analysis of phosphorylated
IκBα expression in the indicated cells; α-Tubulin was used as a loading control.Abbreviations
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